NeurogesX is a specialty pharmaceutical company focused on the development and commercialization of a portfolio of novel non-opioid, pain management therapies to address unmet medical needs. NGSX’ most advanced product candidate, NGX-1998, is a topically applied liquid formulation designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed four phase 1 clinical trials and one phase 2 clinical trial in PHN patients. For more information visit the company’s Web site at www.neurogesx.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: